Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CohBar, Inc. (CWBR)

2.19   0.11 (5.29%) 01-27 15:59
Open: 2.08 Pre. Close: 2.08
High: 2.21 Low: 2.05
Volume: 18,847 Market Cap: 6(M)

Technical analysis

as of: 2023-01-27 4:43:39 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.79     One year: 3.26
Support: Support1: 1.84    Support2: 1.5
Resistance: Resistance1: 2.39    Resistance2: 2.79
Pivot: 2.1
Moving Average: MA(5): 2.14     MA(20): 2.01
MA(100): 2.43     MA(250): 5
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 60.1     %D(3): 62.8
RSI: RSI(14): 60.4
52-week: High: 10.52  Low: 0.17
Average Vol(K): 3-Month: 30 (K)  10-Days: 27 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CWBR ] has closed below upper band by 9.3%. Bollinger Bands are 79% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.21 - 2.22 2.22 - 2.23
Low: 2.03 - 2.04 2.04 - 2.05
Close: 2.17 - 2.19 2.19 - 2.21

Company Description

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Headline News

Wed, 25 Jan 2023
Is CohBar Inc (CWBR) Stock a Good Value Wednesday? - InvestorsObserver

Tue, 17 Jan 2023
Is CohBar Inc (CWBR) Stock a Attractive Value? - InvestorsObserver

Wed, 04 Jan 2023
CohBar Inc (CWBR) Stock Is Up 15.48% This Week: Buy, Hold, or Sell? - InvestorsObserver

Thu, 17 Nov 2022
CohBar (CWBR) retained Ladenburg Thalmann & Co. Inc. as a ... -

Wed, 26 Oct 2022
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022 - Yahoo Finance

Mon, 26 Sep 2022
7 Nasdaq Stocks to Sell Before They Die - InvestorPlace

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 3 (M)
Shares Float 2 (M)
% Held by Insiders 15 (%)
% Held by Institutions 7.1 (%)
Shares Short 39 (K)
Shares Short P.Month 26 (K)

Stock Financials

EPS -0.21
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.44
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -39.6
Return on Equity (ttm) -68.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.83
Qtrly Earnings Growth 0
Operating Cash Flow -10 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -10.85
PEG Ratio 0
Price to Book value 0.33
Price to Sales 0
Price to Cash Flow -0.62

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.